Latest On Bicycle Therapeutics plc (BCYC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-14 14:15 EST | News | Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet | N/A |  |
| 2023-05-10 11:38 EST | News | Bicycle stock jumps on pact with Bayer to develop radiopharmaceuticals for cancer | N/A | |
| 2023-05-04 21:13 EST | News | Bicycle Therapeutics GAAP EPS of -$1.30, revenue of $4.89M | N/A | |
| 2023-03-28 17:17 EST | News | Bicycle stock pops on cancer drug discovery pact with Novartis, gets $50M upfront | N/A | |
| 2023-02-28 15:09 EST | News | Bicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56M | N/A | |
| 2023-02-14 18:15 EST | News | Bicycle Therapeutics posts Phase 1 data for cancer candidate | N/A | |
| 2023-01-04 15:09 EST | News | Bicycle Therapeutics adds 10% on FDA’s fast track tag for bladder cancer therapy | N/A | |
| 2022-11-03 21:35 EST | News | Bicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05, revenue of $3.04M misses by $2.54M | N/A | |
| 2022-10-08 01:53 EST | News | Bicycle Therapeutics: Exploring An Intriguing Developmental Platform | N/A | |
| 2022-09-01 00:39 EST | News | Bicycle Therapeutics initiated Outperform at Cowen citing drug platform | N/A | |
| 2022-08-04 22:13 EST | News | Bicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69M | N/A | |
| 2022-07-12 21:29 EST | News | Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration | N/A | |
| 2022-07-06 01:28 EST | News | Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer | N/A | |
| 2022-05-05 19:05 EST | News | Bicycle Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $3.86M misses by $0.55M | N/A | |
| 2022-04-17 04:20 EST | News | Bicycle Therapeutics: Trying To Catch This Falling Knife | N/A | |
| 2022-04-11 15:59 EST | News | Bicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer data | N/A | |
| 2022-04-11 15:59 EST | News | Bicycle Therapeutics presents at AACR Annual Meeting 2022 - Slideshow | N/A | |
| 2022-04-09 02:28 EST | News | Bicycle Therapeutics gains on early-stage data for oncology asset in bladder cancer | N/A | |
| 2022-03-27 00:04 EST | News | Bicycle Therapeutics: A Buy Ahead Of AACR Presentation | N/A | |
| 2022-03-01 19:32 EST | News | Bicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11M | N/A | |
| 2022-02-28 05:43 EST | News | Bicycle Therapeutics: An Oncology Play With Big Potential | N/A | |
| 2022-01-05 15:44 EST | News | Bicycle Therapeutics COO transitions to CTO; provides clinical program updates | N/A | |
| 2021-11-10 00:38 EST | News | Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next | N/A | |
| 2021-11-04 23:17 EST | News | Bicycle Therapeutics gets dosing underway in early-stage BT7480 cancer trial | N/A | |
| 2021-11-04 23:17 EST | News | Bicycle Therapeutics EPS beats by $0.03, misses on revenue | N/A | |
| 2021-10-26 09:10 EST | News | Genentech exercises option for new immuno-oncology program with Bicycle Therapeutics | N/A | |
| 2021-10-13 15:17 EST | News | Bicycle Therapeutics prices upsized ADS offering at $54 | N/A | |
| 2021-10-12 18:51 EST | News | Bicycle Therapeutics falls 5% on proposed ADS offering | N/A | |
| 2021-10-08 21:15 EST | News | Bicycle Therapeutics draws higher price targets from analysts after cancer study data | N/A | |
| 2021-10-08 01:35 EST | News | Bicycle's shares rise as early-stage candidate shows preliminary anti-tumor activity (updated) | N/A | |
| 2021-08-25 11:00 EST | News | Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles | N/A | |
| 2021-08-05 20:10 EST | News | Bicycle Therapeutics EPS misses by $0.02, misses on revenue | N/A | |
| 2021-07-22 16:37 EST | News | Ionis inks licensing deal with Bicycle Therapeutics to advance LICA technology | N/A | |
| 2021-05-07 01:50 EST | News | Bicycle Therapeutics EPS misses by $0.05, beats on revenue | N/A | |
| 2021-03-18 11:26 EST | Analyst Rating | The Analyst Target Price has increased from $34.88 to $36.75. | Buy | |
| 2021-03-13 18:12 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-12 13:59 EST | Earnings Estimate | An EPS average of -$3.34 is estimated for the 2022 year. | Sell | |
| 2021-03-12 13:59 EST | Earnings Estimate | An EPS average of -$0.59 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-11 21:22 EST | News | Bicycle Therapeutics EPS misses by $0.32, beats on revenue | N/A | |
| 2021-01-21 14:38 EST | Analyst Rating | The Analyst Target Price has increased from $31.38 to $34.88. | Buy | |
| 2021-01-18 06:16 EST | Analyst Rating | The Analyst Target Price has increased from $27.75 to $31.38. | Buy | |
| 2021-01-14 14:35 EST | News | Bicycle Therapeutics gives out pipeline update, shares rise | N/A | |
| 2020-12-04 19:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 10:53 EST | Analyst Rating | The Analyst Target Price has increased from $27.38 to $27.75. | Buy | |
| 2020-12-02 13:28 EST | News | Bicycle Therapeutics settles IP dispute with Pepscan | N/A | |
| 2020-11-27 00:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-09 15:35 EST | Analyst Rating | The Analyst Target Price has decreased from $27.75 to $27.38. | Neutral | |
| 2020-11-06 23:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 10:34 EST | Earnings Estimate | An EPS average of -$0.54 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-06 10:34 EST | Analyst Rating | The Analyst Target Price has increased from $25.5 to $27.75. | Buy | |
About Bicycle Therapeutics plc (BCYC):
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
General
- Name Bicycle Therapeutics plc
- Symbol BCYC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 87
- Fiscal Year EndDecember
- IPO Date2019-05-23
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.bicycletherapeutics.com
View More
Valuation
- Trailing PE 1839
- Price/Sales (Trailing 12 Mt.) 52
- Price/Book (Most Recent Quarter) 6.83
- Enterprise Value Revenue 51.14
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.92
- Next Year EPS Estimate -$3.38
- Next Quarter EPS Estimate -$0.60
- Operating Margin -500%
- Return on Assets -24%
- Return on Equity -54%
- Revenue 10.39 million
- Earnings Per Share -$14.16
- Revenue Per Share $0.54
- Gross Profit -22759000
- Quarterly Earnings Growth -27.1%
View More
Highlights
- Market Capitalization 618.36 million
- EBITDA -24381000
- PE Ratio -6.18
- Analyst Target Price $36.75
- Book Value Per Share $5.33
View More
Share Statistics
- Shares Outstanding 23.09 million
- Shares Float 14.83 million
- % Held by Insiders 2990%
- % Held by Institutions 42.85%
- Shares Short 400080
- Shares Short Prior Month 397139
- Short Ratio 2.76
- Short % of Shares Outstanding 2%
View More
Technicals
- 52 Week High $33
- 52 Week Low $10.5
- 50 Day Moving Average 26.66
- 200 Day Moving Average 21.57
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Bicycle Therapeutics plc (BCYC) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Bicycle Therapeutics plc (BCYC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | -$0.83 | -$0.41 | -101.6% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.52 | -$0.53 | 1.89% |
| 2020-06-30 | 2020-08-05 | $N/A | -$0.67 | -$0.46 | -45.02% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.63 | -$0.38 | -64.36% |
| 2019-12-31 | 2020-03-10 | $5.28 million | -$0.25 | -$0.52 | 51.62% |
| 2019-09-30 | 2019-11-07 | $614000 | -$0.53 | -$0.70 | 23.74% |
| 2019-06-30 | 2019-08-08 | $1.52 million | -$0.66 | -$0.62 | -6.45% |
| 2019-03-31 | 2019-05-23 | $6.38 million | -$0.49 |
Bicycle Therapeutics plc (BCYC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Bicycle Therapeutics plc (BCYC) Chart:
Bicycle Therapeutics plc (BCYC) News:
Below you will find a list of latest news for Bicycle Therapeutics plc (BCYC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bicycle Therapeutics plc (BCYC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-21 | 12.5 | 0 | CALL | 0 | 0 | 77.53 | TRUE | 0 | 0 |
| 2025-03-21 | 15 | 0 | CALL | 0 | 0 | 78.1 | TRUE | 0 | 0 |
| 2025-03-21 | 17.5 | 0 | CALL | 0 | 0 | 73.72 | TRUE | 0 | 0 |
| 2025-03-21 | 20 | 0 | CALL | 0 | 0 | 68.84 | TRUE | 0 | 0 |
| 2025-03-21 | 22.5 | 0 | CALL | 0 | 0 | 64.67 | TRUE | 0 | 0 |
| 2025-03-21 | 25 | 3 | CALL | 17 | 1 | 59.61 | FALSE | 3 | 0 |
| 2025-03-21 | 30 | 3.7 | CALL | 0 | 5 | 76.59 | FALSE | 0 | 0 |
| 2025-03-21 | 35 | 3.31 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 40 | 1.35 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 12.5 | 1 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 17.5 | 1.55 | PUT | 1 | 4 | 68.61 | FALSE | 1.55 | 0 |
| 2025-03-21 | 20 | 2.35 | PUT | 0 | 15 | 72.41 | FALSE | 0 | 0 |
| 2025-03-21 | 22.5 | 3.8 | PUT | 1 | 0 | 67.67 | FALSE | 3.8 | 0 |
| 2025-03-21 | 25 | 0 | PUT | 0 | 0 | 69.85 | TRUE | 0 | 0 |
| 2025-03-21 | 30 | 0 | PUT | 0 | 0 | 68.22 | TRUE | 0 | 0 |
| 2025-03-21 | 35 | 0 | PUT | 0 | 0 | 61.32 | TRUE | 0 | 0 |
| 2025-03-21 | 40 | 0 | PUT | 0 | 0 | 72.06 | TRUE | 0 | 0 |
Latest BCYC Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 200 | $13.335 |
| Jun 13, 2022 7:59 PM EST | 200 | $13.335 |
| Jun 13, 2022 7:59 PM EST | 17 | $13.33 |
| Jun 13, 2022 7:59 PM EST | 975 | $13.3 |
| Jun 13, 2022 7:59 PM EST | 200 | $13.36 |
Bicycle Therapeutics plc (BCYC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm |
| 2020-06-10 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1761612/000000000020005156/0000000000-20-005156-index.htm |
| 2020-09-15 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1761612/000089914020000427/0000899140-20-000427-index.htm |
| 2020-07-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1761612/000092963820000753/0000929638-20-000753-index.htm |
| 2020-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1761612/000104746920002601/0001047469-20-002601-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465919060061/0001104659-19-060061-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465919060805/0001104659-19-060805-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/0001104659-19-062674-index.htm |
| 2019-11-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465919065673/0001104659-19-065673-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465919075599/0001104659-19-075599-index.htm |
| 2020-01-30 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1761612/000110465920008696/0001104659-20-008696-index.htm |
| 2020-02-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1761612/000110465920010545/0001104659-20-010545-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920024459/0001104659-20-024459-index.htm |
| 2020-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920027088/0001104659-20-027088-index.htm |
| 2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920030969/0001104659-20-030969-index.htm |
| 2020-03-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1761612/000110465920031393/0001104659-20-031393-index.htm |
| 2020-04-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920043974/0001104659-20-043974-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920057711/0001104659-20-057711-index.htm |
| 2020-06-05 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1761612/000110465920070493/0001104659-20-070493-index.htm |
| 2020-06-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1761612/000110465920072426/0001104659-20-072426-index.htm |
| 2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm |
| 2020-07-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1761612/000110465920083108/0001104659-20-083108-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920090550/0001104659-20-090550-index.htm |
| 2020-08-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1761612/000110465920090870/0001104659-20-090870-index.htm |
| 2020-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920110716/0001104659-20-110716-index.htm |
| 2020-10-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1761612/000110465920111698/0001104659-20-111698-index.htm |
| 2020-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920111705/0001104659-20-111705-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1761612/000110465920121565/0001104659-20-121565-index.htm |
| 2019-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919119051098/0001209191-19-051098-index.htm |
| 2019-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919119051100/0001209191-19-051100-index.htm |
| 2019-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919119051101/0001209191-19-051101-index.htm |
| 2019-11-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919119055217/0001209191-19-055217-index.htm |
| 2019-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919119061400/0001209191-19-061400-index.htm |
| 2020-01-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001912/0001209191-20-001912-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001917/0001209191-20-001917-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001921/0001209191-20-001921-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001925/0001209191-20-001925-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001930/0001209191-20-001930-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001944/0001209191-20-001944-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001967/0001209191-20-001967-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001981/0001209191-20-001981-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120001990/0001209191-20-001990-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120002003/0001209191-20-002003-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120002011/0001209191-20-002011-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120002019/0001209191-20-002019-index.htm |
| 2020-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120012510/0001209191-20-012510-index.htm |
| 2020-04-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm |
| 2020-04-27 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120025811/0001209191-20-025811-index.htm |
| 2020-04-27 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120025812/0001209191-20-025812-index.htm |
| 2020-04-27 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120025813/0001209191-20-025813-index.htm |
| 2020-04-27 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120025816/0001209191-20-025816-index.htm |
| 2020-04-27 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120025817/0001209191-20-025817-index.htm |
| 2020-08-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120047523/0001209191-20-047523-index.htm |
| 2020-08-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000120919120048252/0001209191-20-048252-index.htm |
| 2020-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1761612/000138713120001831/0001387131-20-001831-index.htm |
| 2020-09-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1761612/000138713120008376/0001387131-20-008376-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1761612/000155837019010277/0001558370-19-010277-index.htm |
| 2020-03-10 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/0001558370-20-002278-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1761612/000155837020005538/0001558370-20-005538-index.htm |
| 2020-08-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1761612/000155837020009277/0001558370-20-009277-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1761612/000155837020012697/0001558370-20-012697-index.htm |
| 2020-06-15 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1761612/999999999520001433/9999999995-20-001433-index.htm |
Bicycle Therapeutics plc (BCYC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bicycle Therapeutics plc (BCYC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 2990%Institutional Ownership: 4285%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-04-14 | Gregory Paul Winter | Director | Buy | 71,450.00 | 163,927.00 | https://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm |